Smead Capital Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$297M Sell
2,471,398
-366,902
-13% -$42.4M 6.47% 3
2025
Q4
$299M Sell
2,838,300
-196,374
-6% -$18.4M 6.2% 2
2025
Q3
$255M Sell
3,034,674
-232,644
-7% -$19.2M 4.92% 6
2025
Q2
$259M Sell
3,267,318
-67,248
-2% -$5.35M 5.18% 4
2025
Q1
$299M Buy
3,334,566
+34,356
+1% +$3.21M 5.13% 5
2024
Q4
$328M Sell
3,300,210
-80,259
-2% -$8.27M 5.09% 6
2024
Q3
$384M Buy
3,380,469
+421,646
+14% +$50.1M 5.48% 5
2024
Q2
$366M Sell
2,958,823
-88,152
-3% -$11.4M 5.72% 4
2024
Q1
$402M Buy
3,046,975
+124,503
+4% +$15.3M 6.27% 3
2023
Q4
$319M Buy
2,922,472
+11,572
+0.4% +$1.2M 5.71% 5
2023
Q3
$300M Sell
2,910,900
-99,873
-3% -$10.8M 6.12% 4
2023
Q2
$347M Sell
3,010,773
-37,019
-1% -$4.2M 6.9% 4
2023
Q1
$324M Buy
3,047,792
+69,193
+2% +$7.47M 6.46% 2
2022
Q4
$330M Buy
2,978,599
+255,497
+9% +$26.1M 7.07% 2
2022
Q3
$235M Buy
2,723,102
+43,226
+2% +$3.86M 6.1% 4
2022
Q2
$244M Buy
2,679,876
+157,342
+6% +$13.9M 6.25% 4
2022
Q1
$207M Buy
2,522,534
+391,023
+18% +$30.8M 4.8% 8
2021
Q4
$163M Buy
2,131,511
+397,372
+23% +$31.7M 4.25% 12
2021
Q3
$130M Buy
1,734,139
+38,828
+2% +$2.95M 4.46% 11
2021
Q2
$132M Buy
1,695,311
+135,892
+9% +$10.1M 4.62% 8
2021
Q1
$115M Buy
1,559,419
+822,494
+112% +$60.7M 5.05% 6
2020
Q4
$57.5M Sell
736,925
-33,142
-4% -$2.53M 3.33% 13
2020
Q3
$61M Sell
770,067
-80,946
-10% -$6.34M 3.86% 10
2020
Q2
$62.8M Sell
851,013
-72,597
-8% -$5.47M 3.96% 11
2020
Q1
$67.8M Sell
923,610
-46,214
-5% -$3.63M 4.81% 8
2019
Q4
$84.2M Buy
969,824
+12,888
+1% +$1.06M 3.74% 12
2019
Q3
$76.9M Sell
956,936
-27,476
-3% -$2.2M 3.76% 15
2019
Q2
$78.8M Sell
984,412
-24,834
-2% -$1.9M 3.79% 13
2019
Q1
$80.1M Sell
1,009,246
-26,163
-3% -$1.96M 4.06% 12
2018
Q4
$75.5M Sell
1,035,409
-42,338
-4% -$2.99M 3.95% 13
2018
Q3
$73M Sell
1,077,747
-28,922
-3% -$1.84M 3.29% 16
2018
Q2
$64.1M Sell
1,106,669
-20,561
-2% -$1.16M 3.05% 18
2018
Q1
$58.6M Sell
1,127,230
-698
-0.1% -$37.7K 2.84% 19
2017
Q4
$60.6M Sell
1,127,928
-53,166
-5% -$2.95M 2.76% 20
2017
Q3
$72.2M Sell
1,181,094
-15,773
-1% -$956K 3.44% 13
2017
Q2
$73.2M Sell
1,196,867
-28,130
-2% -$1.71M 3.53% 14
2017
Q1
$74.3M Sell
1,224,997
-24,305
-2% -$1.47M 3.74% 14
2016
Q4
$70.2M Sell
1,249,302
-160,342
-11% -$9.38M 3.56% 14
2016
Q3
$83.9M Sell
1,409,644
-87,139
-6% -$5.1M 4% 11
2016
Q2
$82.3M Sell
1,496,783
-91,755
-6% -$4.88M 3.86% 14
2016
Q1
$80.2M Sell
1,588,538
-125,252
-7% -$6.13M 3.46% 14
2015
Q4
$71.8M Buy
1,713,790
+438,864
+34% +$22.1M 3.2% 18
2015
Q3
$60.1M Buy
1,274,926
+285,354
+29% +$15.2M 3.21% 19
2015
Q2
$53.8M Buy
989,572
+104,305
+12% +$5.85M 3.51% 14
2015
Q1
$48.6M Buy
885,267
+141,534
+19% +$8.01M 3.57% 14
2014
Q4
$40.3M Sell
743,733
-101,032
-12% -$5.63M 3.71% 12
2014
Q3
$47.8M Buy
844,765
+14,567
+2% +$818K 5.15% 5
2014
Q2
$45.8M Buy
830,198
+38,181
+5% +$2.08M 4.99% 4
2014
Q1
$42.9M Buy
792,017
+97,493
+14% +$5.05M 5.17% 5
2013
Q4
$33.2M Buy
694,524
+201,008
+41% +$9.19M 4.57% 9
2013
Q3
$22.4M Buy
493,516
+76,671
+18% +$3.5M 3.64% 11
2013
Q2
$18.5M Buy
+416,845
New +$18.6M 3.74% 12

Other funds holding MRK

Smead Capital Management's MRK Position: Q1 2026 in Review

Smead Capital Management reduced its Merck (MRK) stake by 13% in Q1 2026, selling an estimated $42.4M and leaving 2,471,398 shares worth $297M. The position accounts for 6.47% of the portfolio, ranked #3.

Smead Capital Management first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $402M in Q1 2024. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Smead Capital Management held 2,471,398 shares of Merck worth $297M as of Q1 2026.
  • Smead Capital Management sold 366,902 Merck shares in Q1 2026, an estimated $42.4M.
  • Merck made up 6.47% of Smead Capital Management's portfolio in Q1 2026, its #3 holding.
  • Smead Capital Management first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Smead Capital Management's Merck position peaked at $402M in Q1 2024.
  • 3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Smead Capital Management's 13F filing for Q1 2026, filed 14 May 2026.